Table 4. Mutation of AML1 related to... | American Society of Hematology

Table 4.

Mutation of AML1 related to clinical and cytogenetic characteristics of 140 patients with t-MDS or t-AML

	AML1 mutated N = 22	AML1 wild-type N = 118	P*
Clinical characteristics
Median age, y	58.5	60	.63†
Female/male	14/8	59/59	.26
Previous treatment
Alkylating agents + cisplatin	19	89	.41
Topoisomerase II inhibitors	9	51	1
Radiotherapy	9	57	1
Median latent period, mo	49	48	.73†
t-MDS	20	69	.003‡
t-AML	2	49
t-MDS → t-AML	15	18	.0001
FAB subtypes of t-MDS at presentation
RA + RARS	6	51	.01§
RAEB + RAEB-t	9	15
CMML	0	1	NS
Unclassifiable t-MDS	5	2	NS
FAB subtypes of t-AML at presentation			NS
M0	0	2
M1	1	9
M2	0	15
M3	0	2
M4	1	11
M5	0	10
Cytogenetic abnormalities
-7/7q-	17	46	.001
-5/5q-	4	30	.59
-17/17p-	1	14	.47
+21/+21q	4	11	.26
+8	4	7	.072
Recurrent balanced translocations	0	22	.025
Normal karyotype	3	21	1
1 or 2 aberrations	8	54	.49
3 or more aberrations	11	43	.24

	AML1 mutated N = 22	AML1 wild-type N = 118	P*
Clinical characteristics
Median age, y	58.5	60	.63†
Female/male	14/8	59/59	.26
Previous treatment
Alkylating agents + cisplatin	19	89	.41
Topoisomerase II inhibitors	9	51	1
Radiotherapy	9	57	1
Median latent period, mo	49	48	.73†
t-MDS	20	69	.003‡
t-AML	2	49
t-MDS → t-AML	15	18	.0001
FAB subtypes of t-MDS at presentation
RA + RARS	6	51	.01§
RAEB + RAEB-t	9	15
CMML	0	1	NS
Unclassifiable t-MDS	5	2	NS
FAB subtypes of t-AML at presentation			NS
M0	0	2
M1	1	9
M2	0	15
M3	0	2
M4	1	11
M5	0	10
Cytogenetic abnormalities
-7/7q-	17	46	.001
-5/5q-	4	30	.59
-17/17p-	1	14	.47
+21/+21q	4	11	.26
+8	4	7	.072
Recurrent balanced translocations	0	22	.025
Normal karyotype	3	21	1
1 or 2 aberrations	8	54	.49
3 or more aberrations	11	43	.24

NS indicates not significant.

If not otherwise indicated, the Fisher exact test (2-sided) was used to determine P value.

Wilcoxon 2-sample test (2-sided).

Calculated among t-MDS and t-AML values.

Calculated among RA + RARS and RAEB + RAEB-t values.